(Q47722459)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16182611%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

title

Reduced exhaled NO is related to impaired nasal potential difference in patients with cystic fibrosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16182611%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

0 references

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16182611%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Isabelle Fajac

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16182611%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

7

Dall'Ava-Santucci J

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16182611%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

author name string

Texereau J

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16182611%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Hubert D

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16182611%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Coste J

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16182611%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Dusser DJ

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16182611%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Bienvenu T

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16182611%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

publication date

22 September 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16182611%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

published in

Vascular Pharmacology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16182611%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

volume

43

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16182611%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16182611%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

page(s)

385-389

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16182611%20AND%20SRC:MED&resulttype=core&format=json

Demonstration That CFTR Is a Chloride Channel by Alteration of Its Anion Selectivity

7 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.08.004

Chloride conductance and genetic background modulate the cystic fibrosis phenotype of Delta F508 homozygous twins and siblings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.08.004

Nitric oxide produced by the enterocyte is involved in the cellular regulation of ion transport

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.08.004

Normal alveolar epithelial lining fluid contains high levels of glutathione

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.08.004

Airway nitric oxide in asthmatic children and patients with cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.08.004

The role of nitric oxide in the regulation of ion channels in airway epithelium: implications for diseases of the lung

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.08.004

Relationships between nasal potential difference and respiratory function in adults with cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.08.004

Perspectives series: host/pathogen interactions. Mechanisms of nitric oxide-related antimicrobial activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.08.004

Cystic fibrosis lung disease: the role of nitric oxide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.08.004

Airway nitric oxide levels in cystic fibrosis patients are related to a polymorphism in the neuronal nitric oxide synthase gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.08.004

Endothelial Nitric Oxide Synthase Variants in Cystic Fibrosis Lung Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.08.004

Correlation between nasal potential difference measurements, genotype and clinical condition in patients with cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.08.004

Exhaled nitric oxide is not elevated in the inflammatory airways diseases of cystic fibrosis and bronchiectasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.08.004

Rethinking cystic fibrosis pathology: the critical role of abnormal reduced glutathione (GSH) transport caused by CFTR mutation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.08.004

DeltaF508 CFTR protein expression in tissues from patients with cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.08.004

Inducible nitric oxide synthase expression is reduced in cystic fibrosis murine and human airway epithelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.08.004

Exhaled and nasal nitric oxide measurements: recommendations. The European Respiratory Society Task Force.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.08.004

Mucus clearance as a primary innate defense mechanism for mammalian airways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.08.004

Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.08.004

The amiloride-inhibitable Na+ conductance is reduced by the cystic fibrosis transmembrane conductance regulator in normal but not in cystic fibrosis airways.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.08.004

Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.08.004

Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.08.004

Nitric oxide in health and disease of the respiratory system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.08.004

Cystic fibrosis transmembrane conductance regulator-dependent regulation of epithelial inducible nitric oxide synthase expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.08.004

The diagnosis of cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.08.004

Nitric oxide synthase 1 as a potential modifier gene of decline in lung function in patients with cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.08.004

Nasal and exhaled nitric oxide is reduced in adult patients with cystic fibrosis and does not correlate with cystic fibrosis genotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.08.004

Nasal airway ion transport and lung function in young people with cystic fibrosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.08.004

Gentamicin-Induced Correction of CFTR Function in Patients with Cystic Fibrosis andCFTRStop Mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.08.004

S-nitrosoglutathione increases cystic fibrosis transmembrane regulator maturation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.08.004

Genotype and phenotype in cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2005.08.004

10.1016/J.VPH.2005.08.004

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16182611%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

1 reference